A gas replacement process and a gas replacement apparatus are employed, in the nitro compound hydrogenation reaction process. The gas replacement process at least includes a first step of subjecting a stream to be replaced to the gas replacement in presence of a first replacement gas, and then a second step of subjecting to the gas replacement in presence of the second replacement gas. Assuming the superficial velocity of the first replacement gas is V1, and the superficial velocity of the second replacement gas is V2, then V2/V1≥1.5.

A gas replacement process and a gas replacement apparatus are employed, in the nitro compound hydrogenation reaction process. The gas replacement process at least includes a first step of subjecting a stream to be replaced to the gas replacement in presence of a first replacement gas, and then a second step of subjecting to the gas replacement in presence of the second replacement gas. Assuming the superficial velocity of the first replacement gas is V1, and the superficial velocity of the second replacement gas is V2, then V2/V1≥1.5.

Aspects of the present disclosure provide for bridgehead-substituted triptycene-based diamines and methods of making bridgehead-substituted triptycene-based diamines.

Processes for stabilizing toluenediamine residues are disclosed. These processes include adding a low viscosity, low boiling liquid to a toluenediamine residue composition to form a blend, and optionally, continuously monitoring the viscosity of the blend during addition of the low viscosity, low boiling liquid. The low viscosity, low boiling liquid may be added at 5% to 30% by weight based on the total weight of the blend. Further, the low viscosity, low boiling liquid may be added so that the blend has a viscosity of 10,000 cP or less throughout the temperature range of 40° C. to 95° C. Blends of toluenediamine residue compositions and low viscosity, low boiling liquids such as water, and methods of their use as a fuel are also disclosed.

Processes for stabilizing toluenediamine residues are disclosed. These processes include adding a low viscosity, low boiling liquid to a toluenediamine residue composition to form a blend, and optionally, continuously monitoring the viscosity of the blend during addition of the low viscosity, low boiling liquid. The low viscosity, low boiling liquid may be added at 5% to 30% by weight based on the total weight of the blend. Further, the low viscosity, low boiling liquid may be added so that the blend has a viscosity of 10,000 cP or less throughout the temperature range of 40° C. to 95° C. Blends of toluenediamine residue compositions and low viscosity, low boiling liquids such as water, and methods of their use as a fuel are also disclosed.

A catalyst including platinum (Pt) and a composite support. The composite support includes ZrO.sub.2/mesoporous silica sieve SBA-15. The platinum accounts for 0.01-0.3 wt. % of the catalyst. ZrO.sub.2 accounts for 5-20 wt. % of the composite support.

A catalyst including platinum (Pt) and a composite support. The composite support includes ZrO.sub.2/mesoporous silica sieve SBA-15. The platinum accounts for 0.01-0.3 wt. % of the catalyst. ZrO.sub.2 accounts for 5-20 wt. % of the composite support.

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

The present invention relates to an activated carbon having an electric conductivity of 3.5 S/cm or more obtained by powder resistance measurement under a load of 12 kN and an oxygen content of 3.0% by mass or more, and a metal-carrying activated carbon using the same, and the like.